- Featured Product
- KD/KO Validated
IL-32 Polyklonaler Antikörper
IL-32 Polyklonal Antikörper für IHC, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human und mehr (1)
Anwendung
WB, IHC, IF, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 11079-1-AP
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in IHC | humanes Lungenkarzinomgewebe, humanes Kolonkarzinomgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Immunhistochemie (IHC) | IHC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| KD/KO | See 1 publications below |
| WB | See 6 publications below |
| IHC | See 6 publications below |
| IF | See 2 publications below |
| ELISA | See 1 publications below |
Produktinformation
11079-1-AP bindet in WB, IHC, IF, ELISA IL-32 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| In Publikationen genannte Reaktivität | human, Maus |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | IL-32 fusion protein Ag1484 |
| Vollständiger Name | interleukin 32 |
| Berechnetes Molekulargewicht | 27 kDa |
| GenBank-Zugangsnummer | BC009401 |
| Gene symbol | IL-32 |
| Gene ID (NCBI) | 9235 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Interleukin 32 (IL32) is a member of the cytokine family. IL32 contains a tyrosine sulfation site, 3 potential N-myristoylation sites, multiple putative phosphorylation sites, and an RGD cell-attachment sequence. IL32 is a predominantly intracellular proinflammatory cytokine produced by epithelial cells, monocytes, T-lymphocytes and natural killer cells, and is involved in inflammation and cancer development. IL32 is able to induce the release a variety of pro-inflammatory cytokines such as IL8, tumor necrosis factor-α (TNFα) and IL6. Expression of this protein is increased after the activation of T-cells by mitogens or the activation of NK cells by IL-2.
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| IHC protocol for IL-32 antibody 11079-1-AP | Protokoll herunterladenl |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
J Cell Mol Med MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway. | ||
J Hepatocell Carcinoma Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology. | ||
Front Pharmacol Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32. | ||
Oncol Lett Interleukin-32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells.
| ||
Oncol Lett Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. | ||
Biomed Res Int IL-32 Promotes the Radiosensitivity of Esophageal Squamous Cell Carcinoma Cell through STAT3 Pathway. |



